Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model

• Published in: Materials today bio Vol. 23; p. 100817
• Main Authors: Lafuente-Gómez, Nuria, de Lázaro, Irene, Dhanjani, Mónica, García-Soriano, David, Sobral, Miguel C., Salas, Gorka, Mooney, David J., Somoza, Álvaro
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2023; Elsevier
• Subjects: Cancer immunotherapy; Cancer vaccine; Full Length; Magnetic nanoparticles; Nanomedicine; Cancer vaccine; Cancer immunotherapy; Nanomedicine; Magnetic nanoparticles
• ISSN: 2590-0064; 2590-0064
• DOI: 10.1016/j.mtbio.2023.100817

Immunotherapy has emerged as a promising strategy to eradicate cancer cells. Particularly, the development of cancer vaccines to induce a potent and sustained antigen-specific T cell response has become a center of attention. Herein, we describe a novel immunotherapy based on magnetic nanoparticles (MNP) covalently modified with the OVA254-267 antigen and a CpG oligonucleotide via disulfide bonds. The MNP-CpG-COVA significantly enhances dendritic cell activation and CD8+ T cell antitumoral response against B16-OVA melanoma cells in vitro. Notably, the immune response induced by the covalently modified MNP is more potent and sustained over time than that triggered by the free components, highlighting the advantage of nanoformulations in immunotherapies. What is more, the nanoparticles are stable in the blood after in vivo administration and induce potent levels of systemic tumor-specific effector CD8 + T cells. Overall, our findings highlight the potential of covalently functionalized MNP to induce robust immune responses against mouse melanoma. [Display omitted]